Monthly Archives - June 2018

Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory diseases, announced that it will be presenting at the Resolution of Inflammation, Infection and Tissue Regeneration Conference in partnership with the New York Academy of Sciences (NYAS), taking place on Tuesday, June 26, 2018 in New York City. Read more >>

Lowell company developing ‘bone glue’ to help healing

Officials at LaunchPad Medical, LLC, say they’re on the right track to breaking ground with this technology. They recently launched their product, Tetranite adhesive, onto the International Space Station for experiments in microgravity environment, and soon will publish the results from those trials. The company is also testing in animals based on strict FDA regulations, and officials hope to get FDA approval in the next year to start testing in humans. Read more >>

Some Guys Have all the Luck

Boston Harbor Angel members, Ziad Moukheiber and David Powsner, are the hosts of Failure – the Podcast, a podcast about about business failures, focusing on startups and emerging companies.
Some guys have all the luck. Some, not so much. How does our guest, Tony Coufal, fare in that regard? You decide. Tony, a serial entrepreneur from Puerto Rico, has be conned by more investors than most people will meet in a lifetime. Still he’s survived — actually, thrived. Join the […]

An MIT Party!

Boston Harbor Angel members, Ziad Moukheiber and David Powsner, are the hosts of Failure – the Podcast, a podcast about about business failures, focusing on startups and emerging companies.
Every Spring, the MIT Enterprise Forum celebrates the entrepreneurship community. Startups from around the globe are invited to a 500+ attendee party to pitch their products, speak with potential business partners and customers. More importantly, they come to relax and celebrate. Join the team from Failure – The Podcast in an […]

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that data from open-label extensions (OLEs) of its systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies are being presented at the Annual European Congress of Rheumatology (EULAR 2018). Read more >>